Large FK506-Binding Proteins Shape the Pharmacology of Rapamycin

REFERENCES

• Proud CG. 2011. mTOR signalling in health and disease. Biochem. Soc. Trans. 39:431–436.
   PubMedGoogle Scholar
• Zoncu R, Efeyan A, Sabatini DM. 2011. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12:21–35.
   PubMed Web of Science ®Google Scholar
• Vezina C, Kudelski A, Sehgal SN. 1975. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. (Tokyo) 28:721–726.
   PubMed Web of Science ®Google Scholar
• Gaali S, Gopalakrishnan R, Wang Y, Kozany C, Hausch F. 2011. The chemical biology of immunophilin ligands. Curr. Med. Chem. 18:5355–5379.
   PubMedGoogle Scholar
• Choo AY, Blenis J. 2009. Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle 8:567–572.
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098–1101.
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM. 2006. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22:159–168.
   PubMed Web of Science ®Google Scholar
• Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, Davis JG, Salmon AB, Richardson A, Ahima RS, Guertin DA, Sabatini DM, Baur JA. 2012. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335:1638–1643.
   PubMed Web of Science ®Google Scholar
• Araki K, Ellebedy AH, Ahmed R. 2011. TOR in the immune system. Curr. Opin. Cell Biol. 23:707–715.
   PubMed Web of Science ®Google Scholar
• Benjamin D, Colombi M, Moroni C, Hall MN. 2011. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat. Rev. Drug Discov. 10:868–880.
   PubMed Web of Science ®Google Scholar
• Bové J, Martinez-Vicente M, Vila M. 2011. Fighting neurodegeneration with rapamycin: mechanistic insights. Nat. Rev. Neurosci. 12:437–452.
   PubMed Web of Science ®Google Scholar
• Saunders RN, Metcalfe MS, Nicholson ML. 2001. Rapamycin in transplantation: a review of the evidence. Kidney Int. 59:3–16.
   PubMed Web of Science ®Google Scholar
• Kozany C, Marz A, Kress C, Hausch F. 2009. Fluorescent probes to characterise FK506-binding proteins. Chembiochem 10:1402–1410.
   PubMed Web of Science ®Google Scholar
• Bai X, Ma D, Liu A, Shen X, Wang QJ, Liu Y, Jiang Y. 2007. Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science 318:977–980.
   PubMed Web of Science ®Google Scholar
• Uhlenbrock K, Weiwad M, Wetzker R, Fischer G, Wittinghofer A, Rubio I. 2009. Reassessment of the role of FKBP38 in the Rheb/mTORC1 pathway. FEBS Lett. 583:965–970.
   PubMedGoogle Scholar
• Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, Lingle W, Petersen G, Lou Z, Wang L. 2009. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 16:259–266.
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. 2004. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14:1296–1302.
   PubMed Web of Science ®Google Scholar
• Schalm SS, Blenis J. 2002. Identification of a conserved motif required for mTOR signaling. Curr. Biol. 12:632–639.
   PubMed Web of Science ®Google Scholar
• Vilella-Bach M, Nuzzi P, Fang Y, Chen J. 1999. The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin-associated protein kinase activity and G1 progression. J. Biol. Chem. 274:4266–4272.
   PubMed Web of Science ®Google Scholar
• Ikenoue T, Hong S, Inoki K. 2009. Monitoring mammalian target of rapamycin (mTOR) activity. Methods Enzymol. 452:165–180.
   PubMed Web of Science ®Google Scholar
• Sato T, Umetsu A, Tamanoi F. 2008. Characterization of the Rheb-mTOR signaling pathway in mammalian cells: constitutive active mutants of Rheb and mTOR. Methods Enzymol. 438:307–320.
   PubMed Web of Science ®Google Scholar
• Dubois S, Shou W, Haneline LS, Fleischer S, Waldmann TA, Muller JR. 2003. Distinct pathways involving the FK506-binding proteins 12 and 12.6 underlie IL-2- versus IL-15-mediated proliferation of T cells. Proc. Natl. Acad. Sci. U. S. A. 100:14169–14174.
   PubMedGoogle Scholar
• Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM, Krissinel EB, Leslie AG, McCoy A, McNicholas SJ, Murshudov GN, Pannu NS, Potterton EA, Powell HR, Read RJ, Vagin A, Wilson KS. 2011. Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67:235–242.
   PubMed Web of Science ®Google Scholar
• Leslie AGW. 1992. Recent changes to the MOSFLM package for processing film and image plate data. Joint CCP4 and ESF-EAMCB Newsletter on Protein Crystallography, no. 26. Daresbury Laboratory, Warrington, UK.
   Google Scholar
• Evans P. 2006. Scaling and assessment of data quality. Acta Crystallogr. D Biol. Crystallogr. 62:72–82.
   PubMedGoogle Scholar
• Liang J, Choi J, Clardy J. 1999. Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 A resolution. Acta Crystallogr. D Biol. Crystallogr. 55:736–744.
   PubMedGoogle Scholar
• Perrakis A, Morris R, Lamzin VS. 1999. Automated protein model building combined with iterative structure refinement. Nat. Struct. Biol. 6:458–463.
   PubMedGoogle Scholar
• Emsley P, Lohkamp B, Scott WG, Cowtan K. 2010. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66:486–501.
   PubMed Web of Science ®Google Scholar
• Murshudov GN, Vagin AA, Dodson EJ. 1997. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53:240–255.
   PubMed Web of Science ®Google Scholar
• Gerard M, Deleersnijder A, Daniels V, Schreurs S, Munck S, Reumers V, Pottel H, Engelborghs Y, Van den Haute C, Taymans JM, Debyser Z, Baekelandt V. 2010. Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson's disease-like pathology. J. Neurosci. 30:2454–2463.
   PubMed Web of Science ®Google Scholar
• Banaszynski LA, Liu CW, Wandless TJ. 2005. Characterization of the FKBP.rapamycin.FRB ternary complex. J. Am. Chem. Soc. 127:4715–4721.
   PubMed Web of Science ®Google Scholar
• Waksman R, Ajani AE, Pichard AD, Torguson R, Pinnow E, Canos D, Satler LF, Kent KM, Kuchulakanti P, Pappas C, Gambone L, Weissman N, Abbott MC, Lindsay J. 2004. Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study. J. Am. Coll. Cardiol. 44:1386–1392.
   PubMed Web of Science ®Google Scholar
• Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS. 2009. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284:8023–8032.
   PubMed Web of Science ®Google Scholar
• Lawrence MC, Colman PM. 1993. Shape complementarity at protein/protein interfaces. J. Mol. Biol. 234:946–950.
   PubMed Web of Science ®Google Scholar
• Heitman J, Movva NR, Hall MN. 1991. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253:905–909.
   PubMed Web of Science ®Google Scholar
• Chen J, Zheng XF, Brown EJ, Schreiber SL. 1995. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc. Natl. Acad. Sci. U. S. A. 92:4947–4951.
   PubMed Web of Science ®Google Scholar
• Hoeffer CA, Tang W, Wong H, Santillan A, Patterson RJ, Martinez LA, Tejada-Simon MV, Paylor R, Hamilton SL, Klann E. 2008. Removal of FKBP12 enhances mTOR-Raptor interactions, LTP, memory, and perseverative/repetitive behavior. Neuron 60:832–845.
   PubMed Web of Science ®Google Scholar
• Price RD, Yamaji T, Yamamoto H, Higashi Y, Hanaoka K, Yamazaki S, Ishiye M, Aramori I, Matsuoka N, Mutoh S, Yanagihara T, Gold BG. 2005. FK1706, a novel non-immunosuppressive immunophilin: neurotrophic activity and mechanism of action. Eur. J. Pharmacol. 509:11–19.
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan R, Kozany C, Gaali S, Kress C, Hoogeland B, Bracher A, Hausch F. 2012. Evaluation of synthetic FK506 analogues as ligands for the FK506-binding proteins 51 and 52. J. Med. Chem. 55:4114–4122.
   PubMedGoogle Scholar
• Gopalakrishnan R, Kozany C, Wang Y, Schneider S, Hoogeland B, Bracher A, Hausch F. 2012. Exploration of pipecolate sulfonamides as binders of the FK506-binding proteins 51 and 52. J. Med. Chem. 55:4123–4131.
   PubMedGoogle Scholar
• Bastidas RJ, Shertz CA, Lee SC, Heitman J, Cardenas ME. 2012. Rapamycin exerts antifungal activity in vitro and in vivo against Mucor circinelloides via FKBP12-dependent inhibition of Tor. Eukaryot. Cell 11:270–281.
   PubMedGoogle Scholar
• Cruz MC, Cavallo LM, Gorlach JM, Cox G, Perfect JR, Cardenas ME, Heitman J. 1999. Rapamycin antifungal action is mediated via conserved complexes with FKBP12 and TOR kinase homologs in Cryptococcus neoformans. Mol. Cell. Biol. 19:4101–4112.
   PubMed Web of Science ®Google Scholar
• Cruz MC, Goldstein AL, Blankenship J, Del Poeta M, Perfect JR, McCusker JH, Bennani YL, Cardenas ME, Heitman J. 2001. Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR. Antimicrob. Agents Chemother. 45:3162–3170.
   PubMed Web of Science ®Google Scholar
• Pemberton TJ. 2006. Identification and comparative analysis of sixteen fungal peptidyl-prolyl cis/trans isomerase repertoires. BMC Genomics 7:244. doi:10.1186/1471-2164-7-244.
   PubMedGoogle Scholar
• Lam E, Martin MM, Timerman AP, Sabers C, Fleischer S, Lukas T, Abraham RT, O'Keefe SJ, O'Neill EA, Wiederrecht GJ. 1995. A novel FK506 binding protein can mediate the immunosuppressive effects of FK506 and is associated with the cardiac ryanodine receptor. J. Biol. Chem. 270:26511–26522.
   PubMed Web of Science ®Google Scholar
• Jiang W, Cazacu S, Xiang C, Zenklusen JC, Fine HA, Berens M, Armstrong B, Brodie C, Mikkelsen T. 2008. FK506 binding protein mediates glioma cell growth and sensitivity to rapamycin treatment by regulating NF-kappaB signaling pathway. Neoplasia 10:235–243.
   PubMed Web of Science ®Google Scholar
• Weiwad M, Edlich F, Kilka S, Erdmann F, Jarczowski F, Dorn M, Moutty MC, Fischer G. 2006. Comparative analysis of calcineurin inhibition by complexes of immunosuppressive drugs with human FK506 binding proteins. Biochemistry 45:15776–15784.
   PubMedGoogle Scholar
• Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D, Peterson TR, Choi Y, Gray NS, Yaffe MB, Marto JA, Sabatini DM. 2011. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332:1317–1322.
   PubMed Web of Science ®Google Scholar
• Yu Y, Yoon SO, Poulogiannis G, Yang Q, Ma XM, Villen J, Kubica N, Hoffman GR, Cantley LC, Gygi SP, Blenis J. 2011. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332:1322–1326.
   PubMed Web of Science ®Google Scholar
• Liu J, Stevens PD, Gao T. 2011. mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells. J. Biol. Chem. 286:6510–6520.
   PubMed Web of Science ®Google Scholar
• Yip CK, Murata K, Walz T, Sabatini DM, Kang SA. 2010. Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol. Cell 38:768–774.
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. 2012. mTOR signaling in growth control and disease. Cell 149:274–293.
   PubMed Web of Science ®Google Scholar
• Takai H, Xie Y, de Lange T, Pavletich NP. 2010. Tel2 structure and function in the Hsp90-dependent maturation of mTOR and ATR complexes. Genes Dev. 24:2019–2030.
   PubMed Web of Science ®Google Scholar
• Nigam SK, Jin YJ, Jin MJ, Bush KT, Bierer BE, Burakoff SJ. 1993. Localization of the FK506-binding protein, FKBP 13, to the lumen of the endoplasmic reticulum. Biochem. J. 294(Pt 2):511–515.
   PubMedGoogle Scholar
• Jin YJ, Burakoff SJ. 1993. The 25-kDa FK506-binding protein is localized in the nucleus and associates with casein kinase II and nucleolin. Proc. Natl. Acad. Sci. U. S. A. 90:7769–7773.
   PubMedGoogle Scholar
• Baughman G, Wiederrecht GJ, Chang F, Martin MM, Bourgeois S. 1997. Tissue distribution and abundance of human FKBP51, and FK506-binding protein that can mediate calcineurin inhibition. Biochem. Biophys. Res. Commun. 232:437–443.
   PubMed Web of Science ®Google Scholar
• Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, Zhang J, Soden R, Hayakawa M, Kreiman G, Cooke MP, Walker JR, Hogenesch JB. 2004. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc. Natl. Acad. Sci. U. S. A. 101:6062–6067.
   PubMed Web of Science ®Google Scholar
• Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandez E, Miller RA. 2009. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460:392–395.
   PubMed Web of Science ®Google Scholar